This paper evaluates the pathogenicity of SARS-CoV-2 BQ.1.1 and BA.5.5 variants in multiple rodent models, finding increased virulence in transgenic mice but not in conventional mice or hamsters.

bioRxiv · Apr 28, 2023 · PreprintMicrobiology

Zbtb46 coordinates angiogenesis and immunity to control tumor outcome

A. U. KABIR, M. SUBRAMANIAN, M. KIM, J. WU, K. KRCHMA, X. WANG, C. M. HALABI, H. PAN, S. A. WICKLINE, D. H. FREMONT, K. CHOI

This study identifies Zbtb46 as a regulator that coordinates angiogenesis and immunity in tumors, with its downregulation promoting a pro-tumor microenvironment and its restoration improving tumor outcomes.

bioRxiv · Mar 2, 2023 · PreprintCancer Biology

Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains

J. B. Case, S. Mackin, J. Errico, Z. Chong, E. A. Madden, B. Guarino, M. A. Schmid, K. Rosenthal, K. Ren, A. Jung, L. Droit, S. A. Handley, P. J. Halfmann, Y. Kawaoka, J. E. Crowe, , M. S. Diamond

This study evaluates the effectiveness of S309 and AZD7442 monoclonal antibodies against Omicron variants in mice, showing reduced lung infection despite decreased neutralization in vitro.

bioRxiv · Mar 17, 2022Microbiology

Isolation of a potently neutralizing and protective human monoclonal antibody targeting yellow fever virus

J. E. Crowe, M. Doyle, J. R. Genualdi, A. Bailey, N. Kose, C. Gainza, J. Rodriguez, K. M. Reeder, C. A. Nelson, P. N. Jethva, R. E. Sutton, R. G. Bombardi, M. Gross, J. G. Julander, D. H. Fremont, M. Diamond

The paper isolates a human monoclonal antibody that neutralizes yellow fever virus and provides therapeutic protection in animal models.

bioRxiv · Feb 28, 2022Immunology

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodies

L. A. VanBlargan, J. M. Errico, P. Halfmann, S. J. Zost, J. E. Crowe, L. A. Purcell, Y. Kawaoka, D. Corti, D. H. Fremont, M. Diamond

This study evaluates the neutralization of the SARS-CoV-2 Omicron variant by therapeutic monoclonal antibodies and finds that several lose efficacy against the variant.

bioRxiv · Dec 15, 2021Microbiology

An intranasal vaccine durably protects against SARS-CoV-2 variants in mice

A. O. Hassan, S. Shrihari, M. J. Gorman, B. Ying, D. Yuan, S. Raju, R. E. Chen, I. P. Dmitriev, E. Kashentseva, L. J. Adams, P.-Y. Shi, D. H. Fremont, D. T. Curiel, G. Alter, M. S. Diamond

This study shows that an intranasal vaccine provides durable protection against SARS-CoV-2 variants in mice, including emerging strains like B.1.351 and B.1.1.28.

bioRxiv · May 8, 2021Microbiology

A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques

A. O. Hassan, F. Feldmann, H. Zhao, D. T. Curiel, A. Okumura, T.-L. Tang-Huau, J. B. Case, K. Meade-White, J. Callison, J. Lovaglio, P. W. Hanley, D. P. Scott, D. H. Fremont, H. Feldmann, M. S. Diamond

A single intranasal dose of ChAd-SARS-CoV-2-S vaccine protects against SARS-CoV-2 infection in rhesus macaques by inducing neutralizing antibodies and T cell responses.

bioRxiv · Jan 26, 2021Microbiology

Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion

S. Ding, R. Zang, J. B. Case, M. F. Gomez Castro, Z. Liu, Q. Zeng, H. Zhao, J. Son, P. W. Rothlauf, G. Hou, S. Bose, X. Wang, M. D. Vahey, T. Kirchhausen, D. H. Fremont, , S. P. J. Whelan

The paper identifies CH25H and its product 25HC as inhibitors of SARS-CoV-2 replication by blocking membrane fusion.

Proceedings of the National Academy of Sciences · Nov 25, 2020Peer-reviewedMicrobiology

Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization

Z. Liu, L. A. VanBlargan, L.-M. Bloyet, P. W. Rothlauf, R. E. Chen, S. Stumpf, H. Zhao, J. M. Errico, E. S. Theel, M. J. Liebeskind, B. Alford, W. J. Buchser, A. H. Ellebedy, D. H. Fremont, M. S. Diamond, S. P. J. Whelan

bioRxiv · Nov 6, 2020 · PreprintMicrobiology

A single intranasal dose of chimpanzee adenovirus-vectored vaccine confers sterilizing immunity against SARS-CoV-2 infection

A. O. Hassan, N. M. Kafai, I. P. Dmitriev, J. M. Fox, B. Smith, I. B. Harvey, R. E. Chen, E. S. Winkler, A. W. Wessel, J. B. Case, E. Kashentseva, B. T. McCune, A. L. Bailey, H. Zhao, L. A. VanBlargan, , M. S. Diamond

A single intranasal dose of ChAd-SARS-CoV-2-S vaccine prevents SARS-CoV-2 infection and likely confers sterilizing immunity in mice.

bioRxiv · Jul 16, 2020 · PreprintMicrobiology

Polyclonal epitope cartography reveals the temporal dynamics and diversity of human antibody responses to H5N1 vaccination

J. Han, A. J. Schmitz, S. T. Richey, Y. Dai, H. L. Turner, B. M. Mohammed, D. H. Fremont, A. H. Ellebedy, A. Ward

This study uses EMPEM to track human antibody responses to H5N1 vaccination, showing persistent stem-binding antibodies and transient head-binding antibodies after immunization.

bioRxiv · Jun 16, 2020Immunology

Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2.

J. B. Case, P. W. Rothlauf, R. E. Chen, Z. Liu, H. Zhao, A. S. Kim, L.-M. Bloyet, Q. Zeng, S. Tahan, L. Droit, M. X. G. Ilagan, M. A. Tartell, G. K. Amarasinghe, J. P. Henderson, S. Miersch, , S. P. J. Whelan

This study develops two neutralization assays for SARS-CoV-2 using VSV and a clinical isolate, showing high concordance between monoclonal, polyclonal antibodies, and ACE2-Fc in neutralizing activity.

bioRxiv · May 18, 2020Microbiology

Structural basis of cowpox evasion of NKG2D immunosurveillance

E. Lazear, M. M. Sun, X. Wang, T. L. Geurs, C. A. Nelson, J. A. Campbell, D. Lippold, A. S. Krupnick, R. S. Davis, L. N. Carayannolpoulos, A. R. French, D. H. Fremont

This study identifies OMCP as a cowpox virus protein that directly binds NKG2D to evade immune detection, revealing structural insights into its high-affinity interaction and zoonotic potential.

bioRxiv · Oct 7, 2019 · PreprintImmunology